دورية أكاديمية
أعرض في EDS

Public Health Responsibilities in the Era of GLP-1 Receptor Agonists.

التفاصيل البيبلوغرافية
العنوان: Public Health Responsibilities in the Era of GLP-1 Receptor Agonists.
المؤلفون: Wang G; Author Affiliations: Trinity College of Arts and Sciences, Duke University, Durham, North Carolina (Ms Wang); School of Computer Science, Carnegie Mellon University, Pittsburgh, Pennsylvania (Ms Rahim); College of Arts & Sciences, Cornell University, Ithaca, New York (Mr Bari); Trinity College of Arts and Sciences, Duke University, Durham, North Carolina (Ms Haque); Trinity College of Arts and Sciences, Duke University, Durham, North Carolina and DSP Health, Granville, Ohio (Mr Rahim); and DSP Health, Granville, Ohio (Dr Palakodeti)., Rahim E, Bari S, Haque H, Rahim FO, Palakodeti S
المصدر: Journal of public health management and practice : JPHMP [J Public Health Manag Pract] 2024 Aug 22. Date of Electronic Publication: 2024 Aug 22.
Publication Model: Ahead of Print
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9505213 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1550-5022 (Electronic) Linking ISSN: 10784659 NLM ISO Abbreviation: J Public Health Manag Pract Subsets: MEDLINE
أسماء مطبوعة: Publication: 2003- : Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Frederick, MD : Aspen Publishers, c1995-
مستخلص: Competing Interests: Conflicts of Interest: The authors declare no conflicts of interest.
References: Miles KE, Kerr JL. Semaglutide for the treatment of Type 2 diabetes mellitus. J Pharm Technol. 2018;34(6):281-289.
Ghusn W, De la Rosa A, Sacoto D, et al. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open. 2022;5(9):e2231982.
Desilver D. As obesity rates rise in the U.S. and worldwide, new weight-loss drugs surge in popularity. Pew Research Center. https://www.pewresearch.org/short-reads/2024/03/21/as-obesity-rates-rise-in-the-us-and-worldwide-new-weight-loss-drugs-surge-in-popularity/#:~:text=Since%20its%202017%20approval%20as,most%20commonly%20prescribed%20drugs%20is. Published 2024. Accessed April 10.
Steepleton J. Managing the spend gain of OZEMPIC. Wellnecity. https://wellnecity.com/newsletters/managing-the-spend-gain-of-ozempic/#:~:text=Weekly%20prescriptions%20for%20OZEMPIC%C2%AE,rather%20than%20Type%202%20diabetes. Accessed April 10, 2024.
Whitley HP, Trujillo JM, Neumiller JJ. Special Report: Potential strategies for addressing GLP-1 and dual GLP-1/GIP receptor agonist shortages. Clin Diabetes. 2023;41(3):467-473.
Lu Y, Liu Y, Krumholz HM. Racial and ethnic disparities in financial barriers among overweight and obese adults eligible for semaglutide in the United States. J Am Heart Assoc. 2022;11(19):e025545.
Warren K How Much Does Wegovy Cost? GoodRx Health. https://www.goodrx.com/wegovy/wegovy-for-weight-loss-cost-coverage. Published 2024. Accessed April 10 2024.
Sforza L. Sanders calls for novo nordisk to slash ozempic, wegovy prices. The Hill. 2024.
Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:996179.
Vajravelu ME, Tas E, Arslanian S. Pediatric obesity: complications and current day management. Life (Basel). 2023;13(7):1591.
Medications containing semaglutide marketed for Type 2 diabetes or weight loss. US Food and Drug Administration. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss. Published 2024. Accessed April 11 2024.
Jamie Nguyen JE, Pawlowski A. To get off-label ozempic prescriptions, some people turn to telehealth websites. https://www.today.com/health/diet-fitness/ozempic-online-prescriptions-weight-loss-rcna68445. Published 2023. Accessed April 11 2024.
Chad Terhune RR Maker of wegovy, ozempic showers money on U.S. obesity doctors. reuters. https://www.reuters.com/investigates/special-report/health-obesity-novonordisk-doctors/. Published 2023. Accessed April 11 2024.
Ezekiel Emanuel JD, McCoy M, Persad G. Fair allocation of GLP-1 and dual GLP-1–GIP receptor agonists. N Engl J Med. 2024;390(20):1839-1842.
Tayag Y BMI Won’t Die. The Atlantic. https://www.theatlantic.com/health/archive/2023/11/bmi-health-obesity-drugs/676171/. Published 2023. Accessed April 11 2024.
Wojtara M, Mazumder A, Syeda Y, Mozgała N. Glucagon-like peptide-1 receptor agonists for chronic weight management. Adv Med. 2023;2023:9946924.
Muller M Ozempic for Kids? Drugmakers test weight-loss shots for 6-Year-Olds. Bloomberg. https://www.bloomberg.com/news/articles/2023-10-20/ozempic-maker-is-testing-weight-loss-drugs-for-kids. Published 2023. Accessed April 11 2024.
Schott G, Pachl H, Limbach U, Gundert-Remy U, Lieb K, Ludwig WD. The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Dtsch Arztebl Int. 2010;107(17):295-301.
Schulthess D, Bowen HP, Popovian R, Gassull D, Zhang A, Hammang J. The relative contributions of NIH and private sector funding to the approval of new biopharmaceuticals. Ther Innov Regul Sci. 2023;57(1):160-169.
Basch SN CH, Tang H, Fera J, Basch CE. Descriptive analysis of TikTok videos posted under the hashtag #ozempic. J Med, Surg, Public Health. 2023;1.
Simon Birk Jensen MB, Michael Sandsdal R, Olsen L, Rimer Juhl C, Rehne Lundgren J, Janus C, Merete Stallknecht B, Juul Holst J, Madsbad S, Sorensen Torekov S. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. eClinicalMedicine. 2024;69(2):102475.
Lewis KH, Moore JB, Ard JD. Game changers: do new medications make lifestyle-based treatment of obesity obsolete? Obesity. 2024;32(2):237-239.
تواريخ الأحداث: Date Created: 20240827 Latest Revision: 20240827
رمز التحديث: 20240828
DOI: 10.1097/PHH.0000000000002039
PMID: 39190662
قاعدة البيانات: MEDLINE
الوصف
تدمد:1550-5022
DOI:10.1097/PHH.0000000000002039